ArticleFrontiers in endocrinology2019

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.

Soo Young Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.